RE:Given time investors will connect the dots...wildbird1 wrote
It is not easy for most peoples(including me) to understand the process of TLT cancer treatment.
Let's resume.
-TLT cancer treatment has a high CR ratio(complete Response) could easily be well over 70%
(70 % is huge).
-TLT cancer treatment has a very low toxicity.
-TLT cancer treatment has a memory response..meaning after the cancer treatment is completed, the patients own immune system start killing cancer cells on it's own.
The three above statements taken alone do not seem much, but taken together it does mean that TLT cancer treatment will be able to treat cancer patients with a weakened immune system, or patients that do not respond to Chemotherapy, or patients that do not respond to Radiation Therapy, and finally treat patients that do not respond to BCG treatment.
That is a lot's of patients.
And the most interesting fact is that TLT cancer treatment doesn't target a very specific cancer cells(like prostate cancer cells), no TLT cancer treatment will target any cancer cells from any cancer(Lung, Brain....).
Valuation...
Once TLT prove that its treatment can cure Prostate cancer, investors will connect the dots and will price the SP value on the many cancer TLT treatment will be able to cure.
The low SP is annoying for now, we just need a little more patience and we will be rewarded big time very soon.
wildbird1 I'm sure you meant to say bladder instead of prostate cancer nevertheless I do agree with you and with this new round of data to validate a high success percentage of CR in the latest patients in both 90 and more importantly continued sustained high CR in the 180 day patients. In my opinion this upcoming data release will be strongly viewed by various funds in North America and Europe, if its as good as most of us feel these funds will be buying up millions of shares with a follow up of their analysts recommendations. ( Just between you and me I think they have been buying in for some time now )